| sess_SDA-2026-04-04- | How do astrocyte-neuron metabolic interactions change during disease progression | 0.86 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a |
| sess_SDA-2026-04-04- | What are the critical protein expression changes and post-translational modifica | 0.68 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| sess_SDA-2026-04-04- | How do peripheral immune system alterations influence CNS pathology and neurodeg | 0.76 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-04- | How do peripheral immune system alterations influence CNS pathology and neurodeg | 0.78 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-04- | How do structural and functional connectivity changes in the human brain connect | 0.71 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-frontier-connectomics-84acb35a |
| sess_SDA-2026-04-09- | The debate mentioned tau PTM targeting but did not identify which modifications | 0.84 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-09- | The debate mentioned tau PTM targeting but did not identify which modifications | 0.71 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-04- | Investigate prion-like spreading of tau pathology through connected brain region | 0.90 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| sess_sda-2026-04-01- | Mitochondrial transfer between neurons and glia? | 0.71 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-20260401231108 |
| sess_sda-2026-04-01- | Protein aggregation cross-seeding across neurodegenerative diseases? | 0.70 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-9137255b |
| sess_sda-2026-04-12- | Which EV-derived biomarkers (phospho-tau, amyloid-beta, synaptic proteins, infla | 0.75 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-12-ev-ad-biomarkers |
| sess_sda-2026-04-01- | PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns | 0.69 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-005 |
| sess_sda-2026-04-01- | RNA binding protein dysregulation across ALS FTD and AD | 0.72 | 3 | 4 | completed | 2026-04-12 | sda-2026-04-01-gap-v2-68d9c9c1 |
| sess_SDA-2026-04-12- | Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn | 0.84 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-12-gap-debate-20260410-112927-b4535f82 |
| sess_SDA-2026-04-04- | How does microglial priming contribute to early Alzheimer's disease pathology? F | 0.80 | 3 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| sess_SDA-2026-04-04- | Investigate mechanistic links between early microglial priming states, neuroinfl | 0.86 | 4 | 4 | completed | 2026-04-12 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| sess_SDA-2026-04-04- | Investigate mechanistic links between early microglial priming states, neuroinfl | 0.95 | 7 | 5 | completed | 2026-04-12 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |
| sess_SDA-2026-04-12- | What is the actual quantitative contribution of FcRn-mediated transcytosis to BB | 0.91 | 7 | 6 | completed | 2026-04-12 | SDA-2026-04-12-gap-debate-20260410-112908-13c403ee |
| sess_sda-2026-04-01- | TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small | 0.84 | 7 | 6 | completed | 2026-04-12 | sda-2026-04-01-gap-006 |
| sess_SDA-2026-04-03- | Does neuroplasticity decline with age? | 0.50 | 0 | 6 | enrolling | 2026-04-11 | |
| DA-2026-04-11-093252 | TDP-43 phase separation therapeutics for ALS-FTD | 0.34 | 0 | 6 | enrolling | 2026-04-11 | |
| DA-2026-04-03-001 | What are novel CRISPR-based therapies for Huntington's disease? | 0.50 | 0 | 7 | enrolling | 2026-04-11 | |
| debate-test-enrollme | Does neuroplasticity decline with age? | 0.50 | 0 | 6 | enrolling | 2026-04-11 | |
| debate-test-gap-enro | Test debate on neuroplasticity mechanisms | 0.50 | 0 | 6 | enrolling | 2026-04-11 | |
| sess_SDA-2026-04-11- | Does reduced Prevotellaceae abundance cause PD pathology or result from it? | 0.95 | 7 | 4 | completed | 2026-04-11 | SDA-2026-04-11-gap-debate-20260410-111558-f9487fea |
| sess_SDA-2026-04-01- | Investigate how lipid raft composition (cholesterol metabolism, sphingolipids) c | 0.93 | 7 | 5 | completed | 2026-04-11 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| sess_SDA-2026-04-11- | TDP-43 phase separation therapeutics for ALS-FTD | 0.95 | 7 | 4 | completed | 2026-04-11 | sda-2026-04-01-gap-006 |
| sess_SDA-2026-04-04- | How do alterations in brain lipid metabolism—including gangliosides, phospholipi | 0.84 | 6 | 4 | completed | 2026-04-11 | SDA-2026-04-04-frontier-lipidomics-dcdbc360 |
| sess_SDA-2026-04-04- | How do peripheral immune system alterations influence CNS pathology and neurodeg | 0.50 | 0 | 4 | completed | 2026-04-11 | SDA-2026-04-04-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-04- | How do structural and functional connectivity changes in the human brain connect | 0.44 | 0 | 4 | completed | 2026-04-11 | SDA-2026-04-04-frontier-connectomics-84acb35a |
| sess_SDA-2026-04-04- | What are the critical protein expression changes and post-translational modifica | 0.56 | 0 | 4 | completed | 2026-04-11 | SDA-2026-04-04-frontier-proteomics-1c3dba72 |
| sess_SDA-2026-04-04- | Epigenetic reprogramming in aging neurons | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| sess_SDA-2026-04-08- | The abstract identifies tissue-specific networks that may underlie Mendelian dis | 0.95 | 7 | 6 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062222-b5f44522 |
| sess_SDA-2026-04-08- | While the abstract mentions identifying subcellular roles of protein interaction | 0.95 | 7 | 7 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47 |
| sess_SDA-2026-04-08- | The abstract shows that dilncRNAs drive molecular crowding of DDR proteins into | 0.90 | 7 | 7 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062229-35a642ca |
| sess_SDA-2026-04-08- | How do host cell factors influence the conformation and propagation properties o | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062207-b800e5d3 |
| sess_SDA-2026-04-08- | While the study shows 53BP1 forms phase-separated foci driven by dilncRNAs, it's | 0.95 | 7 | 7 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062229-3ab00c95 |
| sess_gut-brain-ad | Gut-Brain Axis Therapeutics for Alzheimer's Disease? | 0.94 | 7 | 4 | completed | 2026-04-10 | gut-brain-ad |
| sess_sda-2026-04-01- | Why do entorhinal cortex layer II stellate neurons die first in AD? Their unique | 0.95 | 7 | 6 | completed | 2026-04-10 | sda-2026-04-01-gap-004 |
| sess_sda-2026-04-01- | PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns | 0.91 | 7 | 7 | completed | 2026-04-10 | sda-2026-04-01-gap-005 |
| sess_SDA-2026-04-10- | How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa | 0.94 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| sess_SDA-2026-04-10- | Can circadian interventions reverse microglial priming independent of sleep disr | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 |
| sess_SDA-2026-04-10- | Do different priming stimuli require distinct therapeutic approaches or share co | 0.93 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| sess_SDA-2026-04-10- | What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie | 0.86 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-5407d57d |
| sess_SDA-2026-04-10- | Do tau-containing vesicles exhibit unique surface glycosylation patterns that di | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-d279750b |
| sess_SDA-2026-04-10- | Which specific post-translational modifications on pathological tau create drugg | 0.50 | 0 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd |
| sess_SDA-2026-04-10- | Can nanobodies achieve selective membrane penetration into tau-containing vesicl | 0.95 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 |
| sess_SDA-2026-04-10- | TREM2 Therapeutic Strategy Post-INVOKE-2? | 0.95 | 7 | 4 | completed | 2026-04-10 | trem2-ad |
| sess_SDA-2026-04-10- | Astrocyte reactivity subtypes in neurodegeneration | 0.95 | 7 | 4 | completed | 2026-04-10 | sda-2026-04-01-gap-007 |
| sess_SDA-2026-04-10- | GBA-Synuclein Loop: Therapeutic Strategies for Parkinson's Disease? | 0.89 | 7 | 4 | completed | 2026-04-10 | gba-pd |